NCT01253382View on ClinicalTrials.gov

Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

PHASE2/PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 1, 2012

Primary Completion Date

April 1, 2015

Conditions

Hereditary Angioedema (HAE)

Interventions

BIOLOGICAL

ecallantide

10 - 30mg subcutaneous injection.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY